Nilton Carlos Machado
Research Subjects
Nilton Carlos Machado has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Mary de Assis Carvalho
Universidade Estadual Paulista “Júlio de Mesquita Filho”, Brazil
11 shared publications Juliana Tedesco Dias
7 shared publicationsMary de Assis Carvalho
Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Botucatu Medical School, São Paulo State University, Botucatu, SP, Brazil
6 shared publicationsGabriela Nascimento Hercos
Pediatric Gastroenterology and Hepatology Division Department of Pediatrics Botucatu Medical School-São Paulo State University Brazil
4 shared publications- Carine Dias Ferreira de Jesus
Department of Pediatrics Pediatric Gastroenterology and Hepatology Unit Botucatu Medical School-São Paulo State University Brazil
3 shared publications - Juliana Tedesco Dias
Pediatric Gastroenterology Unit, Department of Pediatrics, Botucatu Medical School -São Paulo State University, Brazil
3 shared publications
Latest Publications
- Open Access
- 17 May 2026
- Published by Qeios Ltd
Review of: "Swiss Ball Exercises for Constipation: Mechanistic Hypothesis, Evidence Quality Assessment, and Clinical Translation Framework"
- 17 May 2026
- Published by Qeios Ltd
Open AccessReview of: "Swiss Ball Exercises for Constipation: Mechanistic Hypothesis, Evidence Quality Assessment, and Clinical Translation Framework"
- Open Access
- 16 December 2025
- Published by AccScience Publishing in Journal of Clinical and Translational Research
- Vol. 12 (1) , 39
Diagnostic delay in very early-onset inflammatory bowel disease: A tertiary single-center retrospective study
Background: Very early-onset inflammatory bowel disease (VEO-IBD) may have an aggressive clinical course. Upon suspicion, an immediate transfer to a pediatric gastroenterology clinic should be made, considering that diagnostic delay (DD) in referral can have profound implications. Objectives: The objectives of the study are to investigate the time, proportion, and factors associated with DD in VEO-IBD and explore the symptoms at initial presentation. Methods: An observational, retrospective, single-center study of consecutive patients with VEO-IBD confirmed by histopathology was conducted. We measured the time to diagnosis—the interval between symptom onset and the final VEO-IBD diagnosis. DD was defined as the time to diagnosis that exceeded the 75th percentile. Results: Twenty-five children with VEO-IBD—16 with ulcerative colitis (UC) and 9 with Crohn’s disease (CD)—were evaluated, with a median age of 34 months. Ages at first symptoms, first visit, and diagnosis were significantly lower for the CD group. However, there was no significant difference in the time from first symptoms to diagnosis between CD and UC. Patients with weight loss, anemia, and fistulas did not meet established criteria for DD and were referred early. Conclusion: Our study underscores the importance of early recognition of VEO-IBD, with bloody diarrhea, abdominal pain, and weight loss serving as crucial warning signs. Identifying these symptoms can aid in the early diagnosis and prompt referral to a specialist, potentially reducing the risk of DD. Relevance for patients: Early recognition of bloody diarrhea, abdominal pain, and weight loss in young children can speed diagnosis of VEO-IBD and ensure timely referral to specialist care.
- 16 December 2025
- Published by AccScience Publishing in Journal of Clinical and Translational Research
- Vol. 12 (1) , 39
Open AccessDiagnostic delay in very early-onset inflammatory bowel disease: A tertiary single-center retrospective study
Background: Very early-onset inflammatory bowel disease (VEO-IBD) may have an aggressive clinical course. Upon suspicion, an immediate transfer to a pediatric gastroenterology clinic should be made, considering that diagnostic delay (DD) in referral can have profound implications. Objectives: The objectives of the study are to investigate the time, proportion, and factors associated with DD in VEO-IBD and explore the symptoms at initial presentation. Methods: An observational, retrospective, single-center study of consecutive patients with VEO-IBD confirmed by histopathology was conducted. We measured the time to diagnosis—the interval between symptom onset and the final VEO-IBD diagnosis. DD was defined as the time to diagnosis that exceeded the 75th percentile. Results: Twenty-five children with VEO-IBD—16 with ulcerative colitis (UC) and 9 with Crohn’s disease (CD)—were evaluated, with a median age of 34 months. Ages at first symptoms, first visit, and diagnosis were significantly lower for the CD group. However, there was no significant difference in the time from first symptoms to diagnosis between CD and UC. Patients with weight loss, anemia, and fistulas did not meet established criteria for DD and were referred early. Conclusion: Our study underscores the importance of early recognition of VEO-IBD, with bloody diarrhea, abdominal pain, and weight loss serving as crucial warning signs. Identifying these symptoms can aid in the early diagnosis and prompt referral to a specialist, potentially reducing the risk of DD. Relevance for patients: Early recognition of bloody diarrhea, abdominal pain, and weight loss in young children can speed diagnosis of VEO-IBD and ensure timely referral to specialist care.
- Open Access
- 1 July 2025
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 14 (4) , 326-331
What can we add to the routine consultation of children and adolescents with functional constipation to make the approach decisively more effective?
What can we add to the routine consultation of children and adolescents with functional constipation to make the approach decisively more effective?
- 1 July 2025
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 14 (4) , 326-331
Open AccessWhat can we add to the routine consultation of children and adolescents with functional constipation to make the approach decisively more effective?
What can we add to the routine consultation of children and adolescents with functional constipation to make the approach decisively more effective?
- Open Access
- 1 January 2025
- Published by Scientific Archives in Archives of Gastroenterology Research
- Vol. 6 (1) , 22-29
Abdominal Migraine in Children and Adolescents at a Single Tertiary Pediatric Gastroenterology Center: A Twelve-yea Experience on Clinical and Therapeutic Findings
Background: Abdominal migraine (AM) may be underdiagnosed and represent a substantial problem for children and their families. Aim: Evaluate the clinical characteristics and the response to prophylactic therapy with Cyproheptadine in children and adolescents with AM. Methods: Observational, retrospective cohort single-center study in consecutive cases of children and adolescents, referred for initial evaluation of chronic abdominal pain at the Pediatric Gastroenterology Outpatient Clinic. Inclusion criteria: Age between 4 and 17 years; Diagnosis of AM defined from structured questionnaires according to three consensus criteria (Rome III, Rome IV criteria, and The International Classification of Headache Disorders). Exclusion criteria: mild symptoms lasting less than one hour and not interfering with daily activities, burning pain, symptoms suggestive of organic disease, or persistence of symptoms between attacks, chronic organic diseases that compromise growth and development include inflammatory bowel disease, celiac disease, and cystic fibrosis. The diagnosis was reviewed during the minimum 6-month follow-up. Results: One hundred forty-seven consecutive patients were diagnosed with AM during the twelve-year study and experienced periodic attacks of abdominal pain, a high proportion in the midline, and intervals of complete absence of symptoms. The most frequently associated symptoms with pain attacks were headache and vomiting. The medians of ages at first visit (8.8 years), age at onset of symptoms (6.5 years), and duration of symptoms (18 months). Positive history of migraine in the mother and family members were 27% and 25%, respectively. Cyproheptadine was the first choice in 81 patients, with appropriate treatment performed in 65 patients and complete resolution in 80%. Conclusions: The current study confirms that a comprehensive history, physical examination, and thoughtful diagnostic criteria are robust for well-defining AM. The findings also reaffirm that prophylactic therapy with Cyproheptadine is highly effective and safe for managing AM in children and adolescents, reassuring the medical community and families of affected children.
- 1 January 2025
- Published by Scientific Archives in Archives of Gastroenterology Research
- Vol. 6 (1) , 22-29
Open AccessAbdominal Migraine in Children and Adolescents at a Single Tertiary Pediatric Gastroenterology Center: A Twelve-yea Experience on Clinical and Therapeutic Findings
Background: Abdominal migraine (AM) may be underdiagnosed and represent a substantial problem for children and their families. Aim: Evaluate the clinical characteristics and the response to prophylactic therapy with Cyproheptadine in children and adolescents with AM. Methods: Observational, retrospective cohort single-center study in consecutive cases of children and adolescents, referred for initial evaluation of chronic abdominal pain at the Pediatric Gastroenterology Outpatient Clinic. Inclusion criteria: Age between 4 and 17 years; Diagnosis of AM defined from structured questionnaires according to three consensus criteria (Rome III, Rome IV criteria, and The International Classification of Headache Disorders). Exclusion criteria: mild symptoms lasting less than one hour and not interfering with daily activities, burning pain, symptoms suggestive of organic disease, or persistence of symptoms between attacks, chronic organic diseases that compromise growth and development include inflammatory bowel disease, celiac disease, and cystic fibrosis. The diagnosis was reviewed during the minimum 6-month follow-up. Results: One hundred forty-seven consecutive patients were diagnosed with AM during the twelve-year study and experienced periodic attacks of abdominal pain, a high proportion in the midline, and intervals of complete absence of symptoms. The most frequently associated symptoms with pain attacks were headache and vomiting. The medians of ages at first visit (8.8 years), age at onset of symptoms (6.5 years), and duration of symptoms (18 months). Positive history of migraine in the mother and family members were 27% and 25%, respectively. Cyproheptadine was the first choice in 81 patients, with appropriate treatment performed in 65 patients and complete resolution in 80%. Conclusions: The current study confirms that a comprehensive history, physical examination, and thoughtful diagnostic criteria are robust for well-defining AM. The findings also reaffirm that prophylactic therapy with Cyproheptadine is highly effective and safe for managing AM in children and adolescents, reassuring the medical community and families of affected children.
- Open Access
- 17 July 2024
- Published by MedCrave Group Kft. in Journal of Pediatrics & Neonatal Care
- Vol. 14 (2) , 138-142
The primary nutritional approach in pediatric celiac disease: a mini-review
Background: Celiac disease (CD) is chronic small bowel inflammation with villous atrophy, consequently, an immune-mediated disorder triggered by ingesting Gluten in wheat, barley, and rye in genetically susceptible individuals. Aims: Summarize the fundamental principles for managing the diet of patients with CD. This Mini-Review using relevant articles in PubMed's online databases followed the medical keywords Celiac Disease, Gluten, gluten-free diet, nutritional approach, and diet adherence. The institution's Ethics Committee has waived the need to review the ethical aspects of this text. The cornerstone of the treatment is the lifelong adherence to a Gluten-Free Diet (GFD). This dietary regimen, which forms the basis of the patient's treatment, requires eliminating all food components containing Gluten and its derivatives from the diet. However, the treatment approach has changed from focusing on food avoidance to a wide-ranging evaluation of the various factors influencing the dietary choices in the patient's life. The Global Approach to the Follow-up of Celiac Disease is based on 1) control of symptomatology and dietary adherence; 2) improving emotional and social wellness in treating CD patients, with the active involvement of a psychologist; and 3) ensuring successful education of both the child and the family about its management. Indeed, the impact of CD extends beyond the patient and affects the well-being of caregivers and 4) evaluate socioeconomic burden, considering that Gluten-free food products remain significantly more expensive than gluten-containing equivalents with variable availability. So, the GFD is the primary treatment for CD, and difficulties in managing the Disease can lead to impaired Quality of Life. In conclusion, strict adherence to the GFD is imperative, requiring a multidisciplinary team involving physicians, dietitians, and psychologists on a regular visit schedule to assess dietary adherence and avoid long-term complications.
- 17 July 2024
- Published by MedCrave Group Kft. in Journal of Pediatrics & Neonatal Care
- Vol. 14 (2) , 138-142
Open AccessThe primary nutritional approach in pediatric celiac disease: a mini-review
Background: Celiac disease (CD) is chronic small bowel inflammation with villous atrophy, consequently, an immune-mediated disorder triggered by ingesting Gluten in wheat, barley, and rye in genetically susceptible individuals. Aims: Summarize the fundamental principles for managing the diet of patients with CD. This Mini-Review using relevant articles in PubMed's online databases followed the medical keywords Celiac Disease, Gluten, gluten-free diet, nutritional approach, and diet adherence. The institution's Ethics Committee has waived the need to review the ethical aspects of this text. The cornerstone of the treatment is the lifelong adherence to a Gluten-Free Diet (GFD). This dietary regimen, which forms the basis of the patient's treatment, requires eliminating all food components containing Gluten and its derivatives from the diet. However, the treatment approach has changed from focusing on food avoidance to a wide-ranging evaluation of the various factors influencing the dietary choices in the patient's life. The Global Approach to the Follow-up of Celiac Disease is based on 1) control of symptomatology and dietary adherence; 2) improving emotional and social wellness in treating CD patients, with the active involvement of a psychologist; and 3) ensuring successful education of both the child and the family about its management. Indeed, the impact of CD extends beyond the patient and affects the well-being of caregivers and 4) evaluate socioeconomic burden, considering that Gluten-free food products remain significantly more expensive than gluten-containing equivalents with variable availability. So, the GFD is the primary treatment for CD, and difficulties in managing the Disease can lead to impaired Quality of Life. In conclusion, strict adherence to the GFD is imperative, requiring a multidisciplinary team involving physicians, dietitians, and psychologists on a regular visit schedule to assess dietary adherence and avoid long-term complications.
- Open Access
- 12 January 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (1) , 164
Transcutaneous Posterior Tibial Nerve Stimulation: An Adjuvant Treatment for Intractable Constipation in Children
Background: Functional constipation can lead to painful defecations, fecal incontinence, and abdominal pain, significantly affecting a child’s quality of life. Treatment options include non-pharmacological and pharmacological approaches, but some cases are intractable and require alternative interventions like neuromodulation. A subtype of neuromodulation, called Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS), comprises electrical stimulation at the ankle level, by means of electrodes fixed to the skin. TPTNS is a minimally invasive, easy-to-apply technique that can potentially improve constipation symptoms in the pediatric population by stimulating the sacral nerves. Aim: To evaluate the clinical results and applicability of TPTNS as an adjuvant treatment for children and adolescents with functional constipation. Methods: Between April 2019 and October 2021, 36 patients diagnosed with functional constipation according to the Rome IV Criteria were invited to participate in the study. The study followed a single-center, uncontrolled, prospective cohort design. Patients received TPTNS for 4 or 8 weeks, with assessments conducted immediately after the periods of TPTNS and 4 weeks after the end of the intervention period. The data normality distribution was determined by the Shapiro–Wilk test. The Wilcoxon test and Student’s t-test for paired samples were used to compare quantitative variables, and the McNemar test was used to compare categorical variables. Results: Of the 36 enrolled patients, 28 children and adolescents with intractable function constipation completed the study, receiving TPTNS for 4 weeks. Sixteen patients (57.1%) extended the intervention period for 4 extra weeks, receiving 8 weeks of intervention. TPTNS led to significant improvements in stool consistency, frequency of defecation, and bowel function scores, with a reduction in abdominal pain. Quality of life across physical and psychosocial domains showed substantial enhancements. The quality of life-related to bowel habits also improved significantly, particularly in lifestyle, behavior, and embarrassment domains. The positive effects of this intervention are seen relatively early, detected after 4 weeks of intervention, and even 4 weeks after the end of the intervention. TPTNS was well-tolerated, with an adherence rate of approximately 78%, and no adverse effects were reported. Conclusions: TPTNS is an adjuvant treatment for intractable functional constipation, improving bowel function and quality of life. The effects of TPTNS were observed relatively early and sustained even after treatment cessation.
- 12 January 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (1) , 164
Open AccessTranscutaneous Posterior Tibial Nerve Stimulation: An Adjuvant Treatment for Intractable Constipation in Children
Background: Functional constipation can lead to painful defecations, fecal incontinence, and abdominal pain, significantly affecting a child’s quality of life. Treatment options include non-pharmacological and pharmacological approaches, but some cases are intractable and require alternative interventions like neuromodulation. A subtype of neuromodulation, called Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS), comprises electrical stimulation at the ankle level, by means of electrodes fixed to the skin. TPTNS is a minimally invasive, easy-to-apply technique that can potentially improve constipation symptoms in the pediatric population by stimulating the sacral nerves. Aim: To evaluate the clinical results and applicability of TPTNS as an adjuvant treatment for children and adolescents with functional constipation. Methods: Between April 2019 and October 2021, 36 patients diagnosed with functional constipation according to the Rome IV Criteria were invited to participate in the study. The study followed a single-center, uncontrolled, prospective cohort design. Patients received TPTNS for 4 or 8 weeks, with assessments conducted immediately after the periods of TPTNS and 4 weeks after the end of the intervention period. The data normality distribution was determined by the Shapiro–Wilk test. The Wilcoxon test and Student’s t-test for paired samples were used to compare quantitative variables, and the McNemar test was used to compare categorical variables. Results: Of the 36 enrolled patients, 28 children and adolescents with intractable function constipation completed the study, receiving TPTNS for 4 weeks. Sixteen patients (57.1%) extended the intervention period for 4 extra weeks, receiving 8 weeks of intervention. TPTNS led to significant improvements in stool consistency, frequency of defecation, and bowel function scores, with a reduction in abdominal pain. Quality of life across physical and psychosocial domains showed substantial enhancements. The quality of life-related to bowel habits also improved significantly, particularly in lifestyle, behavior, and embarrassment domains. The positive effects of this intervention are seen relatively early, detected after 4 weeks of intervention, and even 4 weeks after the end of the intervention. TPTNS was well-tolerated, with an adherence rate of approximately 78%, and no adverse effects were reported. Conclusions: TPTNS is an adjuvant treatment for intractable functional constipation, improving bowel function and quality of life. The effects of TPTNS were observed relatively early and sustained even after treatment cessation.
- Open Access
- 1 January 2024
- Published by Scientific Archives in Archives of Gastroenterology Research
- Vol. 5 (1) , 59-65
Fecal Loading Evaluation by Two Radiological Scores: Comparisons between Functional Constipation and Irritable Bowel Syndrome-Constipation in Children and Adolescents
Aim: Compare fecal loading (FL) using Leech and Starreveld methods in children and adolescents with functional constipation (FC) or irritable bowel syndrome (IBS-C). Methods: Single-center, observational, retrospective, cross-sectional study of consecutive cases referred with unresponsive constipation. Inclusion criteria: FC and IBS-C, according to the Rome IV Criteria, age between 4 and 15 years old. Exclusion criteria: underlying chronic disorders, no medication during the two weeks preceding the radiography. Data collection is executed from electronic medical records. Before the analysis, two pediatric gastroenterologists discussed the methods to ensure an accurate evaluation. The scores were applied to the entire colon. Results: 114 children/adolescents were divided into the FC group (59 patients) and the IBS-C group (55 patients). Baseline characteristics highlight the more prevalent duration of symptoms and painful defecation in FC and female sex, defecation frequency, and abdominal pain in IBS-C. There is a high level of agreement between the two pediatric gastroenterologists in their assessment of FL for both FC and IBS-C, indicating the reliability of the methods. The FL scores in FC were higher than IBS-C, Leech (p<0.001), and Starreveld (p<0.002). The Leech proportion of positive score was FC (93%) and IBS-C (78%), and Starreveld, FC (95%) and IBS-C (89%). Results underscore the effectiveness of the methods in identifying FL. However, in the comparison of the proportion of positive results, FC was higher than IBS-C using only Leech (p<0.02) with Sensitivity (0.93) and Specificity (0.21), and the Starreveld method does not differentiate FC and IBS-C (p=0.30). Conclusions: FC and IBS-C effectively identify groups with differences in FL. Notably, IBS-C had a significantly lower FL score than FC. Thus, the simplicity, low cost, and applicability of the Leech and the Starreveld for observing the FL and gas distribution in the colonic segments may permit better therapeutic planning.
- 1 January 2024
- Published by Scientific Archives in Archives of Gastroenterology Research
- Vol. 5 (1) , 59-65
Open AccessFecal Loading Evaluation by Two Radiological Scores: Comparisons between Functional Constipation and Irritable Bowel Syndrome-Constipation in Children and Adolescents
Aim: Compare fecal loading (FL) using Leech and Starreveld methods in children and adolescents with functional constipation (FC) or irritable bowel syndrome (IBS-C). Methods: Single-center, observational, retrospective, cross-sectional study of consecutive cases referred with unresponsive constipation. Inclusion criteria: FC and IBS-C, according to the Rome IV Criteria, age between 4 and 15 years old. Exclusion criteria: underlying chronic disorders, no medication during the two weeks preceding the radiography. Data collection is executed from electronic medical records. Before the analysis, two pediatric gastroenterologists discussed the methods to ensure an accurate evaluation. The scores were applied to the entire colon. Results: 114 children/adolescents were divided into the FC group (59 patients) and the IBS-C group (55 patients). Baseline characteristics highlight the more prevalent duration of symptoms and painful defecation in FC and female sex, defecation frequency, and abdominal pain in IBS-C. There is a high level of agreement between the two pediatric gastroenterologists in their assessment of FL for both FC and IBS-C, indicating the reliability of the methods. The FL scores in FC were higher than IBS-C, Leech (p<0.001), and Starreveld (p<0.002). The Leech proportion of positive score was FC (93%) and IBS-C (78%), and Starreveld, FC (95%) and IBS-C (89%). Results underscore the effectiveness of the methods in identifying FL. However, in the comparison of the proportion of positive results, FC was higher than IBS-C using only Leech (p<0.02) with Sensitivity (0.93) and Specificity (0.21), and the Starreveld method does not differentiate FC and IBS-C (p=0.30). Conclusions: FC and IBS-C effectively identify groups with differences in FL. Notably, IBS-C had a significantly lower FL score than FC. Thus, the simplicity, low cost, and applicability of the Leech and the Starreveld for observing the FL and gas distribution in the colonic segments may permit better therapeutic planning.
- Open Access
- 22 December 2023
- Published by Scientific Archives in Archives of Gastroenterology Research
- Vol. 4 (1) , 43-51
Pediatric Functional Constipation in Clinical Practice: The Continuous Search for the Light at the End of the Tunnel
Functional constipation (FC) has a pooled world prevalence of 9.5%, a clear definition by Rome IV Criteria, and the NAPGHAN/ESPGHAN guidelines recommendation for management. With well-defined parameters, this commentary discusses the paths followed by the literature to implement different therapeutic modalities over time. The text will prioritize information based on systematic reviews, meta-analyses, or reviews. Recently, an Editorial exploring gastrointestinal diseases across the Lifespan linked constipation as a “vexing issue that, unfortunately, has the potential to impair Health-Related Quality of Life (HRQOL).” Indeed, The Rome Foundation recommended that HRQOL scores may assist in diagnosis, management, prognosis, and therapeutic decisions. Therefore, it can be helpful for clinicians, psychologists, and researchers and could be used to support health services that want to implement an HRQOL program. The final idea is to propose HRQOL as a secondary outcome for Pediatric FC monitoring this disorder.
- 22 December 2023
- Published by Scientific Archives in Archives of Gastroenterology Research
- Vol. 4 (1) , 43-51
Open AccessPediatric Functional Constipation in Clinical Practice: The Continuous Search for the Light at the End of the Tunnel
Functional constipation (FC) has a pooled world prevalence of 9.5%, a clear definition by Rome IV Criteria, and the NAPGHAN/ESPGHAN guidelines recommendation for management. With well-defined parameters, this commentary discusses the paths followed by the literature to implement different therapeutic modalities over time. The text will prioritize information based on systematic reviews, meta-analyses, or reviews. Recently, an Editorial exploring gastrointestinal diseases across the Lifespan linked constipation as a “vexing issue that, unfortunately, has the potential to impair Health-Related Quality of Life (HRQOL).” Indeed, The Rome Foundation recommended that HRQOL scores may assist in diagnosis, management, prognosis, and therapeutic decisions. Therefore, it can be helpful for clinicians, psychologists, and researchers and could be used to support health services that want to implement an HRQOL program. The final idea is to propose HRQOL as a secondary outcome for Pediatric FC monitoring this disorder.
- Open Access
- 21 December 2023
- Published by Xia & He Publishing in Journal of Translational Gastroenterology
- Vol. 1 (2) , 67-73
Overweight/obesity Prevalence and Clinical Features in Children’s Functional Constipation: Descriptive Analysis in a Single Tertiary Center
Functional constipation (FC) and the overweight/obesity (O/O) association are controversial. This study aims to investigate the prevalence of O/O, demographics, and clinical characteristics between children with O/O and normal BMIs, and establish whether O/O constitutes a clinical subgroup.
- 21 December 2023
- Published by Xia & He Publishing in Journal of Translational Gastroenterology
- Vol. 1 (2) , 67-73
Open AccessOverweight/obesity Prevalence and Clinical Features in Children’s Functional Constipation: Descriptive Analysis in a Single Tertiary Center
Functional constipation (FC) and the overweight/obesity (O/O) association are controversial. This study aims to investigate the prevalence of O/O, demographics, and clinical characteristics between children with O/O and normal BMIs, and establish whether O/O constitutes a clinical subgroup.
- Open Access
- 15 December 2023
- Published by MDPI AG in Preprints.org
Transcutaneous posterior tibial nerve stimulation: an adjuvant treatment for intractable constipation in children
BACKGROUND: Functional constipation can lead to painful defecations, fecal incontinence, and abdominal pain, significantly affecting a child's quality of life. Treatment options include non-pharmacological and pharmacological approaches, but some cases are intractable and require alternative interventions like neuromodulation. A subtype of neuromodulation, called Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS), comprises electrical stimulation at the ankle level, by means of electrodes fixed to the skin. TPTNS is a minimally invasive, easy-to-apply technique that can potentially improve constipation symptoms in the pediatric population by stimulating the sacral nerves. AIM: To evaluate the clinical results and applicability of TPTNS as an adjuvant treatment for children and adolescents with functional constipation. METHODS: Between April 2019 and October 2021, 38 patients diagnosed with functional constipation according to the Rome IV Criteria were invited to participate in the study. The study followed a single-center, uncontrolled, prospective cohort design. Patients received TPTNS for 4 or 8 weeks, with assessments conducted immediately after the periods of TPTNS and 4 weeks after the end of the intervention period. The data normality distribution was determined by the Shapiro-Wilk test. Wilcoxon test and Student's t-test for paired samples were used to compare quantitative variables, and the McNemar test was used to compare categorical variables. RESULTS: Of the 38 enrolled patients, 28 children and adolescents with intractable function constipation completed the study, receiving TPTNS for 4 weeks. Sixteen patients (57.1%) extended the intervention period for 4 extra weeks, receiving 8 weeks of intervention. TPTNS led to significant improvements in stool consistency, frequency of defecation, and bowel function scores, with a reduction in abdominal pain. Quality of life across physical and psychosocial domains showed substantial enhancements. The quality of life-related to bowel habits also improved significantly, particularly in lifestyle, behavior, and embarrassment domains. The positive effects of this intervention are seen relatively early, detected after 4 weeks of intervention, and even 4 weeks after the end of the intervention. TPTNS was well-tolerated, with an adherence rate of approximately 78%, and no adverse effects were reported. CONCLUSION: TPTNS is an adjuvant treatment for intractable functional constipation, improving bowel function and quality of life. The effects of TPTNS were observed relatively early and sustained even after treatment cessation.
- 15 December 2023
- Published by MDPI AG in Preprints.org
Open AccessTranscutaneous posterior tibial nerve stimulation: an adjuvant treatment for intractable constipation in children
BACKGROUND: Functional constipation can lead to painful defecations, fecal incontinence, and abdominal pain, significantly affecting a child's quality of life. Treatment options include non-pharmacological and pharmacological approaches, but some cases are intractable and require alternative interventions like neuromodulation. A subtype of neuromodulation, called Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS), comprises electrical stimulation at the ankle level, by means of electrodes fixed to the skin. TPTNS is a minimally invasive, easy-to-apply technique that can potentially improve constipation symptoms in the pediatric population by stimulating the sacral nerves. AIM: To evaluate the clinical results and applicability of TPTNS as an adjuvant treatment for children and adolescents with functional constipation. METHODS: Between April 2019 and October 2021, 38 patients diagnosed with functional constipation according to the Rome IV Criteria were invited to participate in the study. The study followed a single-center, uncontrolled, prospective cohort design. Patients received TPTNS for 4 or 8 weeks, with assessments conducted immediately after the periods of TPTNS and 4 weeks after the end of the intervention period. The data normality distribution was determined by the Shapiro-Wilk test. Wilcoxon test and Student's t-test for paired samples were used to compare quantitative variables, and the McNemar test was used to compare categorical variables. RESULTS: Of the 38 enrolled patients, 28 children and adolescents with intractable function constipation completed the study, receiving TPTNS for 4 weeks. Sixteen patients (57.1%) extended the intervention period for 4 extra weeks, receiving 8 weeks of intervention. TPTNS led to significant improvements in stool consistency, frequency of defecation, and bowel function scores, with a reduction in abdominal pain. Quality of life across physical and psychosocial domains showed substantial enhancements. The quality of life-related to bowel habits also improved significantly, particularly in lifestyle, behavior, and embarrassment domains. The positive effects of this intervention are seen relatively early, detected after 4 weeks of intervention, and even 4 weeks after the end of the intervention. TPTNS was well-tolerated, with an adherence rate of approximately 78%, and no adverse effects were reported. CONCLUSION: TPTNS is an adjuvant treatment for intractable functional constipation, improving bowel function and quality of life. The effects of TPTNS were observed relatively early and sustained even after treatment cessation.